ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndrome Guidelines
| Authors: | Goyal, A.; O'Leary, D.; Dabaja, B.; Weng, W. K.; Zain, J.; Cutler, C.; Guitart, J.; Kim, Y. H.; Geskin, L. J.; Hoppe, R. T.; Wilson, L. D.; Beaven, A. W.; Horwitz, S.; Allen, P. B.; Barta, S. K.; Bohjanen, K.; Brammer, J. E.; Carter, J. B.; Comfere, N.; DeSimone, J. A.; Dusenbery, K.; Duvic, M.; Huen, A.; Jagadeesh, D.; Kelsey, C. R.; Khodadoust, M. S.; Lechowicz, M. J.; Mehta-Shah, N.; Moskowitz, A. J.; Olsen, E. A.; Poh, C.; Pro, B.; Querfeld, C.; Sauter, C.; Sokol, L.; Sokumbi, O.; Wilcox, R. A.; Zic, J. A.; Hamadani, M.; Foss, F. |
| Title: | ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndrome |
| Abstract: | Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma (CTCL). While MF generally follows an indolent course, a subset of patients will experience progressive and/or treatment-refractory disease; Sézary syndrome is an aggressive lymphoma associated with high morbidity and mortality. Although allogeneic hematopoietic cell transplant (allo-HCT) is the only currently available potentially curative treatment modality for MF/SS there is no published guidance on referral criteria, transplant timing orallo-HCT approach. To develop consensus clinical practice recommendations, we performed a Delphi survey of 32 specialists in dermatology (n = 9), transplant hematology/oncology (n = 10), non-transplant hematology/oncology (n = 8), and radiation oncology (n = 5) from across the United States. Consensus required agreement of ≥75% of participants. Sixteen consensus statements were generated on four topics: (1) criteria for referral for consideration for allo-HCT, (2) allo-HCT preparative regimens and procedures (3) disease status at the time of allo-HCT, and (4) multidisciplinary management in the pre- and post-transplant settings. These clinical practice guidelines provide a framework for decision-making regarding allo-HCT for MF/SS and highlight areas for future prospective investigation. © 2024 The American Society for Transplantation and Cellular Therapy |
| Keywords: | transplantation, homologous; allogeneic stem cell transplantation; united states; consensus; skin neoplasms; practice guideline; hematopoietic stem cell transplantation; pathology; skin tumor; cell transformation; practice guidelines as topic; remission; delphi study; clinical practice guideline; epidemiology; mycosis fungoides; therapy; patient referral; allotransplantation; sezary syndrome; humans; human; article; mogamulizumab |
| Journal Title: | Transplantation and Cellular Therapy |
| Volume: | 30 |
| Issue: | 11 |
| ISSN: | 2666-6375 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-11-01 |
| Start Page: | 1047 |
| End Page: | 1060 |
| Language: | English |
| DOI: | 10.1016/j.jtct.2024.08.020 |
| PUBMED: | 39222792 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work